文献速递肿瘤 PET/CT核素与放射性配体治疗

转移性去势抵抗性前列腺癌中序贯PSMA PET/CT评估病灶间肿瘤反应与患者结局

Assessing Interlesional Tumor Response and Patient Outcomes with Sequential PSMA PET/CT in Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2025-09-02

该回顾性研究分析24例接受雄激素受体通路抑制剂治疗的转移性去势抵抗性前列腺癌患者,于基线和治疗第4、12周行[68Ga]Ga-PSMA-11 PET/CT。全局PET/CT反应与总生存、PSA无进展生存等相关,病灶间评估显示第12周病灶间进展者结局更差。

要点

  • 全局PSMA PET/CT反应可区分mCRPC患者结局:PD组中位OS 22个月 vs 非PD组51个月(HR 28.2,P<0.0001)。
  • 第12周病灶间进展与更差结局相关:中位PSA-PFS 7个月 vs 未达到(HR 19.2,P<0.0001)。
  • 第12周病灶间进展者中位OS 16个月 vs 病灶间均匀反应者52个月(HR 31.2,P<0.0001)。

核心结论

  • 通过序贯PSMA PET/CT评估第12周病灶间肿瘤反应,可识别接受雄激素受体通路抑制剂治疗后结局更差的mCRPC患者。

研究设计与样本

  • 回顾性分析24例接受雄激素受体通路抑制剂治疗的mCRPC患者,于基线和治疗第4、12周行[68Ga]Ga-PSMA-11 PET/CT,并于基线和第12周行常规影像。

主要发现

  • 全局PET/CT评估:PD组(n=8)中位OS 22个月 vs 非PD组(n=16)51个月(HR 28.2,P<0.0001)。
  • PD组 vs 非PD组:中位PSA-PFS 6.5个月 vs 未达到(HR 20.5,P=0.0001);中位影像学无进展生存9个月 vs 未达到(HR 12.2,P=0.002);至不再临床获益时间12个月 vs 未达到(HR 18.6,P=0.0002)。
  • 第12周结果与第4周相似且保持统计学显著。
  • 病灶间评估纳入20例(83%)患者的125个PSMA阳性病灶;第12周9/20例(45%)出现病灶间进展。
  • 病灶间进展组 vs 病灶间均匀反应组:中位PSA-PFS 7个月 vs 未达到(HR 19.2,P<0.0001);中位OS 16个月 vs 52个月(HR 31.2,P<0.0001)。

关键数值与推荐

  • 全局PET/CT反应依据欧洲泌尿外科学会/欧洲核医学协会标准分为进展性疾病(PD)或非进展性疾病(非PD,即完全缓解、部分缓解或疾病稳定)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The impact of heterogeneous interlesional tumor response on outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) remains unclear. We aimed to evaluate the role of prostate-specific membrane antigen (PSMA) PET/CT in assessing patient outcomes on the basis of global tumor response and interlesional tumor response. Methods: We retrospectively analyzed data for 24 patients with mCRPC treated with androgen receptor pathway inhibitors who underwent [68Ga]Ga-PSMA-11 PET/CT at baseline and at weeks 4 and 12 of therapy as well as conventional imaging at baseline and week 12 of therapy. Global PET/CT response was evaluated in accordance with the European Association of Urology/European Association of Nuclear Medicine criteria, classifying patients as having progressive disease (PD) or nonprogressive disease (non-PD) (i.e., complete response, partial response, or stable disease) and was correlated with overall survival (OS), prostate-specific antigen-progression-free survival (PSA-PFS) (i.e., time from diagnosis to PSA progression or death from any cause), radiologic progression-free survival, and time to no longer clinically benefiting from treatment. For interlesional assessment, a subset of PSMA-positive lesions was extracted from each patient and compared longitudinally. Patients classified as having either interlesional progression or interlesional homogeneous response were included in the OS and PSA-PFS analyses. Results: The median OS was 22 mo for patients with PD (n = 8) and 51 mo for those with non-PD (n = 16) (hazard ratio [HR], 28.2; P < 0.0001). PSMA PET/CT-based response was significantly associated with median PSA-PFS (6.5 mo vs. not reached [NR]; HR, 20.5; P = 0.0001), radiologic progression-free survival (9 mo vs. NR; HR, 12.2; P = 0.002), and time to no longer clinically benefiting from treatment (12 mo vs. NR; HR, 18.6; P = 0.0002) for patients with PD versus non-PD, respectively. The results were similar at week 12 and remained statistically significant. Interlesional assessment was performed for 125 PSMA-positive lesions in 20 (83%) patients. At week 12, 9 (45%) of 20 patients had interlesional progression, which was significantly associated with worse outcomes compared with patients who had an interlesional homogeneous response (median PSA-PFS, 7 mo vs. NR; HR, 19.2; P < 0.0001; median OS, 16 mo vs. 52 mo; HR, 31.2; P < 0.0001, respectively). Conclusion: Assessment of interlesional tumor response at week 12 by sequential PSMA PET/CT enabled the identification of patients with mCRPC who had worse outcomes after treatment with an androgen receptor pathway inhibitor.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Denis CS, Cousin F, De Laere B, et al. Assessing Interlesional Tumor Response and Patient Outcomes with Sequential PSMA PET/CT in Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2025. PMID: 40744693. doi:10.2967/jnumed.125.269729

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。